What is the bases for treatment selection for immunoglobulin A (IgA) neuropathy according to MHLW/JSN guidelines?

Updated: May 19, 2020
  • Author: Sohail Abdul Salim, MD, FASN, FACP; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Clinical guidelines for managment of IgA nephropathy have been developed by the Japan Ministry of Health Labour and Welfare (MHLW) and the Japanese Society of Nephrology (JSN). [10] These guidelines are meant to to address the clinical situation and establish a standard treatment in Japan, and recommend focusing the managent of IgA nephropathy on prevention of renal dysfunction. Treatments to suppress IgA nephropathy progression are based on the following patient factors:

  • Renal function
  • Urinary protein level
  • Age
  • Renal histopathological findings

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!